Previous 10 | Next 10 |
2023-08-03 10:07:05 ET Prelude Therapeutics press release ( NASDAQ: PRLD ): Q2 GAAP EPS of -$0.54. Cash, cash equivalents, and marketable securities as of June 30, 2023, were $255.0 million. Prelude anticipates that its existing cash, cash equivalents and marketable secu...
Four lead programs on track to deliver clinical data and to inform future development plans Recent equity financing extends cash runway into 2026, enabling advancement of Prelude’s pipeline through critical milestones WILMINGTON, Del., Aug. 03, 2023 (GLOBE NEWSWIRE) -- ...
2023-06-02 17:54:17 ET Summary Today, we take our first look at a small developmental company called Prelude Therapeutics that finds itself deep in Busted IPO Territory. The company came public to raise proceeds to focus on develop small molecule therapies for solid tumors, select...
WILMINGTON, Del., May 31, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Jefferies Healthcare Conference, taking place in New York City, June 7 to 9, 202...
WILMINGTON, Del., May 18, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude" or the "Company") (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its underwritten public offering of 3,048,522 shares of its voting common stock and 1,448,2...
2023-05-17 16:36:10 ET Prelude Therapeutics ( NASDAQ: PRLD ) on Wednesday said it was launching a public offering of common stock and pre-funded warrants of up to $100M. PRLD stock slipped 4.8% to $6 after hours. All of the shares of common stock and pre-funded warrant...
2023-05-08 08:43:57 ET Prelude Therapeutics press release ( NASDAQ: PRLD ): Q1 GAAP EPS of -$0.58 beats by $0.10 . Cash, cash equivalents, and marketable securities as of March 31, 2023, were $172.3 million. Prelude anticipates that its existing cash, cash equivalents ...
Eight abstracts presented at AACR 2023 demonstrate progress of the pipeline Cash runway unchanged, supporting operations into the fourth quarter of 2024 WILMINGTON, Del., May 08, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision ...
WILMINGTON, Del., April 27, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows: ...
WILMINGTON, Del., April 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced details relating to eight abstracts being presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, t...
News, Short Squeeze, Breakout and More Instantly...
Prelude Therapeutics Incorporated Company Name:
PRLD Stock Symbol:
NASDAQ Market:
WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncolog...
WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Life Sciences Conference, taking place in New York City on May 13 a...
First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024 New preclinical data presented at AACR 2024 included first characterization of PRT7732, a highly-selective, orally bioavail...